Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)

被引：0
|
作者：
Ernst, S. M. [1 ]
de Bruijn, P. [2 ]
van der Horst, T. E. [1 ]
Paats, M. S. [1 ]
Aerts, J. G. [1 ]
Mathijssen, R. H. [2 ]
Koolen, S. L. [2 ]
Dingemans, A-M. C. [1 ]
机构：
[1] Erasmus MC Canc Inst, Dept Resp Med, Rotterdam, Netherlands
[2] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1398P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
    Hong, D. S.
    Bang, Y-J.
    Barlesi, F.
    Durm, G.
    Falchook, G. S.
    Govindan, R.
    Dy, G. K.
    Park, K.
    Strickler, J. H.
    Burns, T. F.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1390
  • [22] Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
    Hong, D. S.
    Bang, Y-J.
    Barlesi, F.
    Durm, G. A.
    Falchook, G. S.
    Govindan, R.
    Dy, G. K.
    Park, K.
    Strickler, J. H.
    Burns, T. F.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    ANNALS OF ONCOLOGY, 2020, 31 : S812 - S812
  • [23] COST PER RESPONDER ANALYSIS COMPARING ADAGRASIB AND SOTORASIB IN PATIENTS WITH KRAS G12C-MUTATED PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
    Berardi, A.
    Laurie, M.
    Theriou, C.
    Orsini, I
    Bouwmeester, W.
    Gao, S.
    Korytowsky, B.
    VALUE IN HEALTH, 2023, 26 (12) : S119 - S120
  • [24] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [25] The KRYSTAL-1 study of adagrasib - a new trial for KRASG12C-mutated non-small-cell lung cancer
    Murciano-Goroff, Yonina R.
    Lito, Piro
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (11) : 677 - 678
  • [26] Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the Era of Immunotherapy (IO)
    Stenehjem, D.
    Lubinga, S.
    Betts, K. A.
    Tang, W.
    Jenkins, M.
    Yuan, Y.
    Hartman, J.
    Rao, S.
    Lam, J.
    Waterhouse, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S17 - S17
  • [27] Sotorasib in KRAS G12C-mutated non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 846 - 846
  • [28] The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
    Yonina R. Murciano-Goroff
    Piro Lito
    Nature Reviews Clinical Oncology, 2022, 19 : 677 - 678
  • [29] Outcome of KRAS mutated (m) non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (immuneCl).
    Aranda, Nuria Pardo
    Viaplana, Cristina
    Remon, Jordi
    Marti, Alex Martinez
    Perez, Susana Cedres
    Navarro, Alejandro
    de Castro, Ana Maria Martinez
    Villacampa, Guillermo
    Carbonell, LLuisa
    Hernando, Alberto
    Vivancos, Ana
    Dienstmann, Rodrigo
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
12345